anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ARDS is a serious condition that involves lung inflammation and fluid accumulation in the air sacs, leading to low blood oxygen levels and respiratory failure. It is often fatal and affects approximately 160,000 individuals each year in the United States. The main form of treatment for ARDS is delivery of oxygen and a continuous level of pressure to the damaged lungs through mechanical ventilation. However, some methods of mechanical ventilation may cause ventilator-associated lung injury (VALI), a condition that can result from overdistension of the lungs during inspiration or from excessive mechanical forces. VALI can delay or prevent healing from respiratory failure.

HFOV is a mechanical ventilation method that pumps small amounts of air into the lungs at a constant high rate. Because the increments of air are small the likelihood of experiencing overdistension and developing VALI may be reduced. While HFOV is an effective, commonly used ventilation method, there have been no studies that demonstrate the efficacy of HFOV in comparison to the efficacy of conventional mechanical ventilation methods. This study will compare two different HFOV techniques: the HFOV-Hi method, which uses higher airway pressure, and the HFOV-Lo method, which uses lower airway pressure. The purpose of this study is to compare the safety and efficacy of HFOV-Hi, HFOV-Lo, and standard mechanical ventilation methods in individuals with ARDS.

This study will enroll individuals with ARDS at four Baltimore hospitals. Participants will be randomly assigned to receive either HFOV-Hi or HFOV-Lo. All participants will receive their assigned HFOV method for 7 days, until spontaneous breathing occurs, or until death, whichever occurs first. Blood collected at baseline and Days 1 and 3 will be analyzed for markers of inflammation and lung injury. Participants' clinical status will be monitored until they no longer need ventilation and return home, or for up to 60 days while in the hospital. Individuals being treated for ARDS at the participating hospitals who decline to enroll in the study will be asked for permission to monitor their medical progress. These individuals will not take part in any study procedures, but their clinical information will be used for comparison purposes. Additionally, clinical information on other ARDS patients admitted to the hospital over the previous 2 years will be analyzed.
The Copenhagen General Population Study (CGPS) is an ongoing observational population study with more than 110.000 participants from the greater Copenhagen area. All residents in the greater Copenhagen area \> 40 years and 25% of 20-40 years old are invited to participate in the study and in follow-up examinations every decade. A random sample of 10.000 participants aged ≥ 40 years had a contrast enhanced CT of the chest including CT angiography of the heart performed. Of these, 6500 had a contrast enhanced CT of the abdomen.
The invention relates to an application of QianJinDingZhi total saponin, and especially relates to an application of QianJinDingZhi total saponin in preparing a medicine used for treating senile dementia. First, QianJinDingZhi total saponin has an intelligence improving effect. The QianJinDingZhi total saponin has a substantial ameliorating effect against mice learning and memory disorder model caused by chemical medicines scopolamine, sodium nitrite, and ethanol. Compared with a model group, the error latency period of a medicated group is substantially prolonged, and the error frequency of the medicated group is substantially reduced. The total saponin has substantial ameliorating effect against learning and memory dysfunction of subacute aging mice caused by D-galactose and learning and memory hypofunction of old mice. With the QianJinDingZhi total saponin, monoamine neurotransmitter content in old rat brain can be increased, and activity of cholinesterase in old rat brain can be reduced. The QianJinDingZhi total saponin has an anti-aging effect. QianJinDingZhi total saponin assists in substantially improving activity of SOD in serum and brain tissue of subacute aging mice caused by D-galactose and learning and old mice, in substantially reducing MDA content, and in improving the thymus index of the subacute aging mice caused by D-galactose.
The CBT condition will probe sleep reactivity using validated CBT strategies over 6 sessions in accordance with the two-factor theory of emotion. Behavioral strategies will be used to reduce physiological arousal (e.g., relaxation training, breathing) and to strengthen behavioral cues for sleep (e.g., sleep hygiene and sleep scheduling). Sleep times will be scheduled to align with the reduced circadian misalignment (compromised phase position, i.e., maintaining a slightly delayed sleep period on offwork days). Cognitive strategies will identify stressors (e.g., dysfunctional beliefs about sleep) and intervene on worry and rumination with cognitive reappraisal and active coping. Sessions will be conducted by a trained behavioral sleep medicine provider via telemedicine to increase accessibility.
Objective: To construct and characterize conditional Src homology region 2 protein tyrosine phosphatase 1 (SHP-1) knockout mice in airway epithelial cells and to observe the effect of defective SHP-1 expression in airway epithelial cells on the emphysema phenotype in chronic obstructive pulmonary disease (COPD). Methods: To detect the expression of SHP-1 in the airway epithelium of COPD patients. CRISPR/Cas9 technology was used to construct SHP-1flox/flox transgenic mice, which were mated with airway epithelial Clara protein 10-cyclase recombinase and estrogen receptor fusion transgenic mice (CC10-CreER+/+), and after intraperitoneal injection of tamoxifen, airway epithelial SHP-1 knockout mice were obtained (SHP-1flox/floxCC10-CreER+/-, SHP-1Δ/Δ). Mouse tail and lung tissue DNA was extracted and PCR amplified to discriminate the genotype of the mice; the knockout effect of SHP-1 gene in airway epithelial cells was verified by qRT-PCR, Western blotting, and immunofluorescence. In addition, an emphysema mouse model was constructed using elastase to assess the severity of emphysema in each group of mice. Results: Airway epithelial SHP-1 was significantly downregulated in COPD patients. Genotyping confirmed that SHP-1Δ/Δ mice expressed CC10-CreER and SHP-1-flox. After tamoxifen induction, we demonstrated the absence of SHP-1 protein expression in airway epithelial cells of SHP-1Δ/Δ mice at the DNA, RNA, and protein levels, indicating that airway epithelial cell-specific SHP-1 knockout mice had been successfully constructed. In the emphysema animal model, SHP-1Δ/Δ mice had a more severe emphysema phenotype compared with the control group, which was manifested by disorganization of alveolar structure in lung tissue and rupture and fusion of alveolar walls to form pulmonary alveoli. Conclusions: The present study successfully established and characterized the SHP-1 knockout mouse model of airway epithelial cells, which provides a new experimental tool for the in-depth elucidation of the role of SHP-1 in the emphysema process of COPD and its mechanism.
PURPOSE: A solid dispersion containing amorphous selecoxib is provided to ensure excellent elusion rate and storage stability and to be applied to a solid pharmaceutical composition for oral administration. CONSTITUTION: A solid dispersion contains 100 parts by weight of selecoxib, 20-60 parts by weight of water soluble polymers, and 5-30 parts by weight of surfactant. The surfactant is sodium lauryl sulfate. The solid dispersion additionally contains 1-5 parts of by weight of organic acid. The organic acid includes citric acid, tartaric acid, malic acid, succinic acid, acetic acid, sorbic acid, adipic acid, formic acid, furmaric acid, or gluconic acid. A pharmaceutical composition for selectively suppressing cyclooxygenase-2(COX-2) contains the solid dispersion as an active ingredient. A pharmaceutical composition for preventing or treating pain or inflammatory diseases contains the solid dispersion as an active ingredient.
Breast cancer is the most common form of cancer among women. Axillary surgical procedures have reported, with post-operative morbidity of bleeding, lymphedema and shoulder pain, also the rather underestimated Axillary Web Syndrome. The study shows that the reduction of the problems linked to the Syndrome such as pain in shoulder Abduction and Flexion and inability in everyday life is possible with an early and competent treatment. Two different approaches to the Syndrome were investigated. The patients were divided in two groups. Good results were obtained within 5 weeks since the appearance of AWS with both of them but if the Physiotherapist is able to teach the convenient exercises, the selftreatment seemed to have the best outcome. This fact can change the awareness that an early approach is necessary inside the path to recovery. In the last years the Axillary Web Syndrome was the topic of many studies: the etiology, its clinical diagnosis, the relation with lymphedema...But the treatment was often reported like a combination of different techniques without indications about kinds, times. Instead the investigators examined a detailed procedure, the same in both groups. The work was different only as regards the cords treatment. This fact shows the value of a comprehensive treatment for neck, shoulder, breast and two different but specific works on the Axillary Web Syndrome. For these reasons its publishing could be important for all the professionals working with women after Surgery for breast cancer and metastatic lymphnodes.
<P>PROBLEM TO BE SOLVED: To provide a novel thalidomide analog expected to have pharmacological activity such as an antitumor effect.  <P>SOLUTION: L-glutamic acid or L-aspartic acid is converted into a dimethyl ester, and then the amino group therein is protected. Next, the dimethyl ester in which the amino group is protected is converted into an imide, and then a protecting group is removed, thereby obtaining a hydrochloride of 3-aminoglutarimide or a hydrochloride of 3-aminosuccinimide. Next, the hydrochloride of the imide obtained by the procedures is condensed with a desired natural amino acid, the protecting group is removed from the resultant amino acid condensation compound, and then 4-nitrophenyl chloroformate is reacted therewith. A thalidomide analog having a hydantoin moiety is thus obtained.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Identified herein are different forms of bitter receptor genes that occur in different humans. These alleles are generated by numerous coding single nucleotide polymorphisms (cSNP's) that occur within the members of the T2R gene family. Some SNP's cause amino acid substitutions, while others introduce chain termination codons, rendering the allele non-functional. Differences in these genes are believed to have a large effect on those individuals' sense of bitter taste, such that these individuals perceive the taste of bitter substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define large groups and populations who perceive bitter tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level for the first time.
Despite free ARV drugs and free TB treatment, and an expanding DOTS program, TB rates have not diminished in this city overall (29), suggesting that DOTS alone will not be sufficient to turn the tide. Nevertheless, an elemental ACF strategy did appear to work well in this city. A prior International Collaborations in Infectious Disease Research (ICIDR), in one area of Rio de Janeiro, evaluated the use of the WHO's directly observed therapy, short course (DOTS) strategy versus an enhanced DOTS strategy (DOTS-A), which included household contact investigation as a means of identifying cases. A statistically significant reduction in incidence rates between DOTS versus DOTS-A communities was seen from 2000 to 2002 (Figure 2), suggesting that ACF strategies can be instrumental in reducing incidence rates if subjects are detected and treated. Treatment completion rates among new TB cases were not significantly different statistically in the 2 study arms, however treatment completion rates overall increased from 68% to 77% over the course of the study. Overall, the DOTS communities exhibited little change (+7%) in TB incidence over the 5-year period, while DOTS-A communities showed a combined decrease (-14%) (P\<0.05). The difference suggests that a large scale ACF campaign at a more intensive level (ie, door-to-door case finding) could have a significant impact on long-term TB incidence in a community.
The present invention relates to a device for purifying and treating water, and belongs to the technical field of a water treatment device for environmental protection science. The device is composed of a water supply system, a cooling system, a vacuum system, a quality guarantee system, a pollution discharge system, a control system, etc. The techniques of spraying atomization, vaporizing separation, vacuum negative pressure, etc. are used, and an automatic control technique is combined. The device of the present invention for purifying and treating water can effectively remove impurities from raw water, and have no secondary pollution and choking phenomena. The device has the advantages of original concept, compact structure, high efficiency and low energy consumption, and can automatically and continuously purify, and automatically discharge pollution. The device of the present invention for purifying and treating water is suitable to treat various kinds of water, including water supply, sewage and sea water desalination.
Participants will independently complete cognitive exercises on the "Smartbrain Pro" computer software. These exercises aim to train different aspects of executive function. The difficulty level of each exercise will increase relative to each participant's progress. Sessions will last for one hour, occurring twice weekly for a period of 4 weeks.
The present invention provides a method of increasing the efficacy of treating a muscle or sweat gland hyperactivity condition in a human or mammal with a neurotoxin. The method includes adding a quantity of either a diffusion-limiting agent or an anti-metabolic agent to the neurotoxin. Adding the agent to the neurotoxin leads to the formation of an agent/neurotoxin injection mixture. The quantity of agent added is sufficient to increase a therapeutic response of the human or mammal's sweat gland or muscle to the neurotoxin compared to what the response would have been had the human or mammal been treated with neurotoxin alone. The present invention provides a kit for treating a muscle or sweat gland hyperactivity condition in a human or mammal. The kit includes a needle, a solvent, a neurotoxin, and either a diffusion-limiting agent or an anti-metabolic agent.
Septoria nodorum blotch (SNB), caused by Parastagonospora nodorum, is a disease of durum and common wheat initiated by the recognition of pathogen-produced necrotrophic effectors (NEs) by specific wheat genes. The wheat gene Snn1 was previously cloned, and it encodes a wall-associated kinase that directly interacts with the NE SnTox1 leading to programmed cell death and ultimately the development of SNB. Here, sequence analysis of Snn1 from 114 accessions including diploid, tetraploid, and hexaploid wheat species revealed that some wheat lines possess two copies of Snn1 (designated Snn1-B1 and Snn1-B2) approximately 120 kb apart. Snn1-B2 evolved relatively recently as a paralog of Snn1-B1, and both genes have undergone diversifying selection. Three point mutations associated with the formation of the first SnTox1-sensitive Snn1-B1 allele from a primitive wild wheat were identified. Four subsequent and independent SNPs, three in Snn1-B1 and one in Snn1-B2, converted the sensitive alleles to insensitive forms. Protein modeling indicated these four mutations could abolish Snn1-SnTox1 compatibility either through destabilization of the Snn1 protein or direct disruption of the protein-protein interaction. A high-throughput marker was developed for the absent allele of Snn1, and it was 100% accurate at predicting SnTox1-insensitive lines in both durum and spring wheat. Results of this study increase our understanding of the evolution, diversity, and function of Snn1-B1 and Snn1-B2 genes and will be useful for marker-assisted elimination of these genes for better host resistance.
PURPOSE: To provide a moisture holding compsn. excellent in moisture retention and good in stability and a base agent containing the same. CONSTITUTION: A moisture holding compsn. consists of trihydric or more water- soluble polyhydric alcohol, lecithin, 3-methyl-1,3-butylene glycol and, if desired, water. An oily substance and/or water are compounded with this compsn. to prepare a viscous or gel like base agent, an oil in water type emulsified base agent or a solubilizing base agent.
FIELD: medicine, pharmaceutical industry. SUBSTANCE: invention relates to methods of preparing biologically active preparations from reindeer horns. Ossified horns of reindeer males are ground to particle size 2 mm, not above, extracted with 25-35% ethyl alcohol three times, then with 50% ethyl alcohol twice in the ratio raw to extractant = 1:10 being each extraction is performed for 5 h at the room temperature and constant stirring. Then extracts obtained with 25-35% alcohol are evaporated to an aqueous residue and extracts with 50% alcohol to viscous mass. The combined extract is diluted with pure extractant, settled, filtered and the liquid extract of horn raw 1:1 in 30% alcohol is obtained. EFFECT: expanded arsenal of agents with adaptogenic activity, enhanced biological activity of preparation. 10 tbl, 3 ex
The controversy over the equivalence of continuous sedation until death (CSD) and physician-assisted suicide/euthanasia (PAS/E) provides an opportunity to focus on a significant extended use of CSD. This extension, suggested by the equivalence of PAS/E and CSD, is designed to promote additional patient autonomy at the end-of-life. Samuel LiPuma, in his article, "Continuous Sedation Until Death as Physician-Assisted Suicide/Euthanasia: A Conceptual Analysis" claims equivalence between CSD and death; his paper is seminal in the equivalency debate. Critics contend that sedation follows proportionality protocols for which LiPuma's thesis does not adequately account. Furthermore, sedation may not eliminate consciousness, and as such LiPuma's contention that CSD is equivalent to neocortical death is suspect. We not only defend the equivalence thesis, but also expand it to include additional moral considerations. First, we explain the equivalence thesis. This is followed by a defense of the thesis against five criticisms. The third section critiques the current use of CSD. Finally, we offer two proposals that, if adopted, would broaden the use of PAS/E and CSD and thereby expand options at the end-of-life.
The present invention relates to compound cetirizine hydrochloride gel which belongs to the technical field of medicine. Aiming at the disadvantage that an external preparation of cetirizine hydrochloride has not the function of sterilization or bacteriostasis, the compound cetirizine hydrochloride gel of the present invention contains the following ingredients: 100.0g of cetirizine hydrochloride, 0.5 to 2g of mupirocin, 5.0 to 10.0g of substrate, 60 to 100 ml of glycerol or propanediol, and 5.0 to 10.0g of triethanolmine in each 1000g of gel. A right amount of PBS is added, a pH value is regulated to be from 6 to 7, and distilled water is added until 1000g is reached. The compound cetirizine hydrochloride gel is gel which contains 10% of cetirizine. Through clinic verification, the compound cetirizine hydrochloride gel has the good function of antianaphylaxis and good tolerance without a side reaction for the whole body. The compound cetirizine hydrochloride gel has the good clinical application prospect. The compound cetirizine hydrochloride gel adopts macromolecule gel forming material, the appearance is transparent and uniform, the physical stability is good, the compatibility for the skin is good, the penetrating power is strong, and therefore, the therapeutic effect is strengthened. The gel is easily coated, washed and removed without oiliness. The normal function of the skin can not be influenced. A user feels comfortable.
A retrospective chart review will be performed for all patients presenting to the ED with agitation and subsequently given antipsychotic therapy for treatment. Identification of patients will be through chart review of patients presenting with agitation. Data to be recorded include patient age, gender, medical history, time of presentation, time of treatment, co morbidities, use of restraint, time to disposition and patient outcome. Inclusion criteria include all patients over age 18 presenting to the ED with agitation and treated with antipsychotics. No patients will be knowingly excluded from analysis. We will compare resulting outcomes of patients treated for agitation to see if Adasuve is superior to other commonly prescribed antipsychotics through its rate of discharge home and overall time in the emergency department.
In leukemogenesis, genotoxic stress in hematopoietic stem and progenitor cells (HSPCs) drives individual context-dependent programs of malignant transformation. In light of the various differentiation stages of HSPCs based on a recently revised definition using CD150/CD48, our analyses showed that a subpopulation of long-term repopulating HSCs was most susceptible to MLL-ENL-mediated transformation. An analysis of the molecular mechanism identified Bromo-adjacent homology domain and coiled-coil containing 1 (Bahcc1), which encodes a reader molecule of trimethylated histone H3 lysine 27 (H3K27me3), as a candidate gene involved in distinct susceptibility to leukemic transformation. Interestingly, Bahcc1 was previously reported to be highly expressed in acute myeloid leukemia (AML) with an unfavorable prognosis, including some cases of MLL-rearranged AML. We found that MLL-ENL upregulated Bahcc1 through binding to its promoter, and that Bahcc1 was involved in MLL-ENL-mediated immortalization at least partly through repression of H3K27me3-marked Cdkn1c. Analyses using bone marrow transplantation in mice showed that depletion of Bahcc1 suppressed the leukemogenic activity of MLL-ENL. In a public database, high BAHCC1 expression was found to be associated with a poor prognosis in pediatric AML, in which BAHCC1 expression was significantly lower in MLL-AF9-AML than in other MLL-fusion-AML. These findings shed light on the distinct immortalization potential of HSPCs and suggest a novel MLL-fusion-Bahcc1 axis, which may lead to development of molecular targeted therapy against MLL-fusion-mediated leukemia.